BNP improves outcomes in evaluation of dyspnoea
BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7451.0-f (Published 27 May 2004) Cite this as: BMJ 2004;328:0-fQuestion Does use of the test for B-type natriuretic peptide (BNP) in the diagnosis of acute dyspnoea improve patients' outcomes?
Synopsis Too often, new tests are introduced without a careful examination of their effect on patient oriented outcomes. Accuracy alone is not reason enough to adopt a test; a more important reason is that its use helps patients live better or longer lives. We should also know whether is adds or reduces cost. There is previous convincing evidence that B-type natriuretic peptide is accurate in diagnosing heart failure in patients presenting with acute dyspnoea (N Engl J Med 2002;106:416-22). This latest randomised controlled trial (single blinded) study is the first to look at the larger …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.